Impairment in glial lymphatic "glymphatic" flow is hypothesized to be an etiologic factor in the development of Alzheimer’s disease (AD). We report a quantitative study of glymphatic flow in man, combining intrathecal administration of gadobutrol (macrocylic gadolinium-based contrast agent) with serial T1-mapping to produce contrast concentration maps up to 3 days post-injection. This demonstrates proof-of-concept feasibility and offers data on the pharmacokinetics of glymhatic flow.
This abstract and the presentation materials are available to members only; a login is required.